Log In
Print
BCIQ
Print
Print this Print this
 

Vesomni, solifenacin/tamsulosin (EC905)

  Manage Alerts
Collapse Summary General Information
Company Astellas Pharma Inc.
DescriptionFixed-dose combination of solifenacin and tamsulosin
Molecular Target
Mechanism of Action 
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentApproved
Standard Indication Genitourinary (unspecified)
Indication DetailsTreat lower urinary tract symptoms associated with benign prostatic hyperplasia (BPH); Treat moderate to severe storage symptoms and voiding symptoms associated with benign prostatic hyperplasia (BPH)
Regulatory Designation

Partner


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today